For pharmacies, hospitals, distributors and pharma field teams, using it well is part of professional practice. Here is what it does and how to build it into the working week.

What the Med Safety app is

Med Safety is a smartphone app for reporting suspected adverse drug reactions to the National Agency for Food and Drug Administration and Control (NAFDAC). It was launched in Nigeria in November 2020 and was promoted widely during the COVID-19 vaccine rollout, when NAFDAC encouraged health workers and the public to report side effects through it.

In June 2026 NAFDAC released an upgraded version, as reported by Brand Spur. According to that report, the new version:

• lets users report suspected substandard or falsified medicines, such as packs with altered expiry dates or questionable packaging, as well as side effects;
• has a simpler reporting screen;
• lets users upload photos and detailed descriptions of a suspect product to support an investigation;
• gives better feedback, so people who report hear back about their case.

NAFDAC officials have urged the public not to keep quiet about bad reactions, explaining that reports are monitored and can lead to an investigation and, where a product is found to be unsafe, its withdrawal.

Why reports from professionals matter most

A report is only as useful as its detail. Pharmacists, nurses, doctors and trained sales staff are best placed to record the details an investigator needs: the product name and strength, the batch number and expiry date, where it was bought, what happened and when, and what else the patient was taking. A photo of the pack, the label and the batch number can save days of follow-up.

Professionals also see patterns. A cluster of complaints about one batch, a pack that looks slightly different from usual, or a supplier offering prices that seem too good to be true are early signals that are easy to miss if nobody writes them down.

The older tool: scratch-and-text codes

Some medicine packs in Nigeria carry a scratch panel with a one-time code. This is NAFDAC's Mobile Authentication Service (MAS), introduced in 2010 and extended in 2012 to anti-malarials and antibiotics. The consumer texts the code to a short code and receives a reply saying whether the product is genuine. Where a pack has a MAS panel, it is a quick extra check at the counter. A failed or suspicious check is exactly the kind of thing to report through Med Safety.

Building reporting into your routine

• Install it on the right phones. The pharmacy's main phone, the ward or dispensary phone, and the phones of supervisors and field staff.
• Name a pharmacovigilance lead. One person in each pharmacy, ward or sales team who checks that suspected reactions and suspect products are reported, and who keeps a simple log.
• Capture details at the counter. Train staff to note the batch and expiry, and to keep the pack or take photos, before the customer leaves.
• Tell the manufacturer or supplier too. Marketing authorisation holders have their own safety obligations, and a report to them alongside NAFDAC helps both sides act faster.
• Protect patient privacy. Share only what the report needs. Health information is sensitive personal data under the Nigeria Data Protection Act.
• Include it in field visits. Pharma reps who hear about a side effect during a visit should know their company's process and pass it on the same day.

This is general information, not legal or regulatory advice. Follow NAFDAC's current guidance and your own company's pharmacovigilance procedures.

A small habit with a big effect

Most people who notice a problem with a medicine never report it. Each report from a pharmacy, ward or field team adds to the evidence NAFDAC uses to keep unsafe and fake products off the market. Making the Med Safety app part of everyday practice costs a few minutes and protects patients, customers and the reputation of every honest supplier.

Sources: NAFDAC statements on reporting adverse drug reactions via the Med Safety app, as reported by Gazette Nigeria and TheCable (2020 launch); Brand Spur report on NAFDAC's upgraded Med Safety app (June 2026); reports on NAFDAC's Mobile Authentication Service by Outsourcing-Pharma (2010) and SafeMedicines.

What the policy is

In June 2024 President Bola Tinubu signed an executive order setting zero tariffs, excise duties and VAT on specified machinery, equipment and raw materials for healthcare production in Nigeria. It was part of the Presidential Initiative for Unlocking the Healthcare Value Chain, launched in 2023 to grow local production of medicines and medical products.

The Nigeria Customs Service announced on 26 March 2025 that it had begun applying a two-year exemption from import duty and VAT on critical inputs for local pharmaceutical manufacturing, following a directive approved through the Minister of Finance. According to the Customs statement, the inputs covered include:

• active pharmaceutical ingredients (APIs) and excipients;
• other raw materials for making essential medicines;
• reagents and packaging materials;
• inputs for long-lasting insecticidal nets and rapid diagnostic kits.

Who qualifies

Customs said eligibility is restricted to pharmaceutical manufacturers recognised by the Federal Ministry of Health and Social Welfare, and that they must hold a valid Tax Identification Number. Customs also said it would compile quarterly reports on everything imported under the policy.

In other words, this is a support for factories, not for traders. A company that imports finished, packed medicines for resale is not the target of this waiver.

What it could mean for prices and supply

Customs said the policy is expected to significantly lower production costs. Lower input costs give local manufacturers room to price more competitively, invest in capacity, or both. Over time that can mean more locally made options on a pharmacy shelf or a hospital tender, and less exposure to delays at ports and foreign suppliers.

It is sensible to keep expectations realistic, though. Raw-material duties are only one part of a manufacturer's costs. Exchange rates, energy, financing, distribution and regulatory costs all still matter, and a manufacturer decides for itself how much of a saving reaches its price list. Industry voices have welcomed the waiver while asking for the policy to stay consistent, because factories plan investment over years, not months.

The clock is running

Because the exemption was announced as a two-year measure from early 2025, it is due to run until around the first quarter of 2027 unless the government extends or changes it. Buyers who agree long supply contracts or annual tenders should be aware that input costs for local manufacturers could change when the window closes.

This is general information, not legal, tax or regulatory advice. Check the current position with the Nigeria Customs Service, the Federal Ministry of Health and Social Welfare, and your own advisers before making decisions.

What hospital, pharmacy and distributor buyers can do now

• Know where your products are made. Ask suppliers which lines are manufactured in Nigeria and which are imported finished. It helps you anticipate where costs and lead times may move.
• Ask about pricing plans. When you renew a supply agreement, it is fair to ask a local manufacturer how input-cost changes are reflected in its prices, and for how long quoted prices hold.
• Keep quality checks the same. Whether a product is local or imported, confirm its NAFDAC registration number, batch and expiry, and buy only through licensed channels.
• Watch for updates. Look out for the Customs quarterly reports and any announcement about extending the waiver beyond its two years.
• Plan for 2027. If you run annual tenders, build a review point around the end of the waiver into contracts that run past early 2027.

The bigger picture

Policies like this are only one part of building a reliable local medicines industry. Steady demand from hospitals, pharmacies and distributors who are willing to give quality local products a fair hearing matters just as much. The waiver lowers one barrier; buyers and suppliers working together on forecasting, payment terms and quality will decide how much difference it makes.

Sources: Nigeria Customs Service statement on the two-year import duty and VAT exemption for pharmaceutical raw materials (26 March 2025), as reported by Nairametrics and BusinessDay; the June 2024 presidential executive order on healthcare value chain inputs, as reported by Nairametrics and The Guardian Nigeria.

1. Decide who you are talking to

"Healthcare professionals" is too broad to write for. Pick two or three audiences and write each post for one of them:

• Buyers: hospital procurement teams, pharmacy owners and wholesalers who care about availability, quality, price and reliable delivery.
• Clinicians and pharmacists: who want practical, accurate information and little else.
• Industry peers and partners: manufacturers looking for a Nigerian distributor, sales leaders, investors and others who follow how the market is changing.
• Future staff: reps, pharmacists and graduates deciding whether you are a company worth joining.

2. Post useful things, not adverts

The posts that travel on LinkedIn teach something or show something real. Good formats for a pharma or health company include:

• Short explainers on regulation, supply or market changes and what they mean for buyers.
• Behind-the-scenes posts on quality: storage, cold chain, and how you check batches and documents.
• Lessons from the field, such as what makes a rep visit useful to a busy pharmacist.
• People posts: a new hire, a training day, a team that hit a hard target. Real faces build more trust than stock images.
• A link to a longer article on your own website, so readers who want more land somewhere you control.

A simple rule of thumb: for every post that asks for something (a demo, an order, an application), publish several that only give.

3. Respect the rules on promoting medicines

LinkedIn is a public platform, so treat everything on a company page as advertising to the general public. In Nigeria, NAFDAC regulates the advertising of medicines and other regulated products, and prescription-only medicines should not be promoted to the public. In practice that means:

• Keep product claims off LinkedIn unless your regulatory team has approved them for public use.
• Talk about your company, your service, your quality systems and the wider market rather than the clinical benefits of a prescription product.
• Never share patient information or identifiable photos from clinics without written consent, and remember that the Nigeria Data Protection Act applies to what you post.
• Keep a simple approval step for posts, even if it is one person checking before anything goes live.

This is general information, not legal or regulatory advice. Check current NAFDAC requirements, and any industry codes your company follows, with your regulatory or legal team.

4. Use people, not just the page

Company pages usually reach far fewer people than individuals do. The most effective approach combines both: the company page publishes, and the managing director, sales leaders and medical team reshare it with a sentence of their own view. Encourage staff to keep their profiles current and to say where they work. A rep whose profile is clear and professional is easier for a pharmacist or hospital buyer to trust before the first visit.

5. Be consistent rather than busy

One good post a week, every week, beats a burst of ten followed by silence. A weekly rhythm is realistic for a small team: publish a useful article on your website, share it on LinkedIn with a short summary in your own words, and reply to comments within a day. Connecting your website's RSS feed to your LinkedIn page can automate the sharing step, so the habit does not depend on someone remembering.

6. Measure what matters

Likes are easy to count and easy to misread. Track a few numbers that connect to the business:

Review these every month, keep doing what works and drop formats that nobody engages with.

1. Agree what a tier means

A tier is a short label that tells everyone how important an account is to your brands. Many teams use four levels, for example:

The frequencies above are only a starting point. Set your own based on your products, the length of your cycle and how many working days a rep really has in the field.

2. Tier on potential, not just on habit

The most common mistake is tiering by how often a rep already visits someone. Instead, score each account on a few simple questions:

• Potential: how many relevant patients does this doctor, clinic or pharmacy see?
• Current support: do they already prescribe or stock your brands?
• Influence: do other prescribers follow their lead (a KOL), or do they decide what the hospital or pharmacy buys?
• Access: can you realistically see them, and at what times?

Record the answers on the account profile, not in a notebook, so the tier survives when a rep changes territory.

3. Check that the plan fits the calendar

Add up the visits your tiers demand and compare them with the time available. A simple check:

1. Count working days in the cycle and subtract leave, meetings, training and public holidays.
2. Multiply by the number of quality calls a rep can make per day in that territory. Traffic in Lagos is not the same as in a smaller town, so be honest.
3. Compare the result with the total visits your tiers require.

If the plan needs more calls than the days allow, do not just ask reps to "push harder". Move some T2 accounts to T3, extend the cycle, or rebalance territories. A plan reps cannot finish quickly stops being taken seriously.

4. Cluster visits by area

Once you know who to see and how often, group accounts that are close together so each day has a sensible route. Put the strategic accounts early in the cycle, so there is time to try again if a doctor is unavailable, and leave a few free slots for follow-ups and unplanned opportunities.

5. Review the plan with the manager

The first-line manager should approve each rep's plan before the cycle starts. A short review catches common problems: a key account missing, too many visits to one favourite, or a week that is impossible to complete. If a plan goes back, the reason should be written down so the rep can fix it quickly.

6. Track coverage, not just call counts

During the cycle, watch two numbers per tier: the share of accounts seen at least once, and the share of planned visits completed. A rep who makes many calls but misses half of their ST accounts has a coverage problem, not an activity problem. Review the tiers at the end of each cycle and move accounts up or down based on what you have learned.

Before the visit: set one clear objective

Every call should have one main objective that the rep can check afterwards. "Detail product X" is an activity, not an objective. Better examples:

• Agree with the doctor which type of patient the product could suit.
• Answer the pharmacist's question about stock availability and get an order or a date to follow up.
• Confirm who in the hospital decides on formulary additions and how to submit a request.
• Invite the doctor to an upcoming CME and get a yes or no.

Spend two minutes reviewing the account before the visit: what was discussed last time, what was promised, and whether samples or materials were requested. If the last call ended with an open question, answering it should usually be today's objective.

During the visit: listen first, then present

• Open with their agenda. Ask what has changed since your last visit and what they need. A short question often tells you more than a full presentation.
• Keep the message focused. Pick the one or two points that match the objective and the person in front of you. Use approved material only, and do not make claims beyond the approved product information.
• Notice what holds attention. If a doctor lingers on a slide or asks about one point, that is useful information for the next visit.
• Close with a clear next step. Agree what happens next and when: a follow-up visit, information to send, a sample request, or an order.

After the visit: record it while it is fresh

Write the call note within the same day, ideally before the next visit. A good note answers four questions:

1. Was the objective met? If not, why not?
2. What did the customer say that matters: needs, objections, questions?
3. What did we agree as the next step, and by when?
4. What should the next visit focus on?

Turn every promise into a task with a due date. Sending a requested study summary or confirming a delivery date within the time you promised is one of the simplest ways to build trust.

What pharmacy and hospital buyers value

For pharmacies, hospital pharmacies and procurement teams, the most helpful rep visits tend to be practical:

• Accurate information on availability, pack sizes and registration status.
• Clear, honest answers on delivery times and who to call when there is a problem.
• Respect for their time: visits at agreed hours, short and to the point.
• Follow-up that actually happens, without having to chase it.

For managers: coach the objective, not just the activity

When managers join visits, the most useful coaching usually focuses on the objective and the close: was the objective specific, did the rep listen before presenting, and did the call end with an agreed next step? Short, regular coaching notes are easier to act on than a long review once a quarter.

The Nigeria Data Protection Act 2023 (NDPA) sets the rules for how organisations handle personal data about people in Nigeria, and it established the Nigeria Data Protection Commission to oversee them. A pharma CRM is full of personal data: names, phone numbers and email addresses of doctors and pharmacists, notes from conversations, visit locations and the details of the reps who use it. That makes the CRM one of the first places to look when you review your data protection practices.

What counts as personal data in a pharma CRM?

Any information that relates to an identifiable person. In a typical field CRM this includes:

• Healthcare professionals' names, specialties, workplaces and contact details.
• Call notes, preferences and anything recorded about what a doctor said.
• Reps' and managers' own data: sign-in details, GPS check-ins, activity and coaching notes.
• Signatures captured for sample receipts, and attendance at events or CMEs.

Information about patients' health is sensitive personal data and needs extra care. As a rule, a commercial CRM should not hold patient-identifiable information at all; train reps to keep call notes about the professional conversation, not about individual patients.

Controller or processor: who is responsible?

The company that decides why and how the data is used is the data controller. For CRM data, that is normally the pharmaceutical company or distributor whose reps collect it. A software provider that stores or handles the data on the company's behalf is usually a data processor, acting on the controller's instructions. Your contract with any CRM provider should make these roles clear.

The principles to build around

The NDPA expects personal data to be handled according to principles that will feel familiar to anyone who knows other modern data protection laws:

• Lawful, fair and transparent: have a lawful basis for keeping each type of data, and tell people what you hold and why.
• Purpose limitation: use data for the purposes you collected it for, not for something unrelated.
• Data minimisation: keep only what you need. Free-text fields often collect more than anyone intended.
• Accuracy: keep records up to date, and correct them when asked.
• Storage limitation: decide how long you keep data and delete what you no longer need.
• Security and confidentiality: protect data against loss and unauthorised access.
• Accountability: be able to show how you comply, not just say it.

Rights of the doctors and pharmacists in your records

The people in your CRM have rights under the Act, including to be informed, to access their data, to have it corrected or deleted in appropriate cases, and to object to certain uses. In practice your team needs a simple way to find everything held about one person, correct it, and remove it when that is the right outcome, and someone who knows how to respond to a request on time.

Practical steps for a pharma sales team

1. Map what you hold. List the CRM fields, attachments and exports, and who can see them.
2. Limit access by role. Reps should see their own territory, managers their team. Avoid shared logins.
3. Control exports. CSV exports and spreadsheets on personal laptops are a common weak point. Agree who may export and where files are kept.
4. Know where the data is stored. Ask your CRM provider where your records live, who can access them and which sub-processors are involved.
5. Keep an audit trail. A log of who changed what helps with accuracy and with investigating problems.
6. Plan for incidents. The Act requires certain personal data breaches to be reported to the Commission quickly, generally within 72 hours of becoming aware of them, so have a plan before you need it.
7. Train the field team. Short, practical guidance on what to write in call notes does more than a long policy nobody reads.

Depending on the volume and type of data it processes, an organisation may also be classed as a data controller or processor "of major importance", with extra obligations such as registering with the Commission. Check the current NDPC guidance to see whether this applies to you.

Questions to ask any CRM provider

• Where is our data stored, and can we get all of it back in a usable format?
• Who at the provider can see our records, and when?
• Can access be restricted by role and territory?
• Is there an audit log of changes?
• If AI features are used, what data is sent, to whom, and can we turn them off?